Tumour and organ microenvironments are crucial for cancer progression and metastasis. Crosstalk between multiple non-malignant cell types in the microenvironments and cancer cells promotes tumour growth and metastasis. Blood and lymphatic endothelial cells (BEC and LEC) are two of the components in the microenvironments. Tumour blood vessels (BV), comprising BEC, serve as conduits for blood supply into the tumour, and are important for tumour growth as well as haematogenous tumour dissemination. Lymphatic vessels (LV), comprising LEC, which are relatively leaky compared with BV, are essential for lymphogenous tumour dissemination. In addition to describing the conventional roles of the BV and LV, we also discuss newly emerging roles of these endothelial cells: their crosstalk with cancer cells via molecules secreted by the BEC and LEC (also called angiocrine and lymphangiocrine factors). This review suggests that BEC and LEC in various microenvironments can be orchestrators of tumour progression and proposes new mechanismbased strategies to discover new therapies to supplement conventional antiangiogenic and anti-lymphangiogenic therapies.
Among the crucial cell types in the tumour and organ microenvironments, blood and lymphatic endothelial cells (BEC and LEC) are the components of blood vessels (BV) and lymphatic vessels (LV), respectively (Refs 13, 14) . Tumour BV play a role as conduits for blood supply into the tumour, which is pivotal for tumour growth. These BV also contribute to haematogenous tumour cell spreading. Tumour LV are particularly important for metastasis, as the LV are only sparsely covered by pericytes and smooth muscle cells, and thus more permeable compared with BV (Ref. 15) . These are among the reasons that in certain cancers, such as breast cancer, tumour dissemination occurs preferentially via stromal and peritumoural LV. The conventional roles of BV and LV are limited to their functions as conduits for the delivery of oxygen, nutrients, lymph fluid and for metastatic tumour cells. Roles of the factors secreted by BV and LV and the signals mediated by them in the promotion of cancer and metastasis in particular are relatively less well understood. Recently, it has been reported that the cells lining the blood (BEC) and lymphatic (LEC) vessels exhibit distinct gene expression profiles (Ref. 16) , suggesting that BV and LV and the diverse set of proteins they secrete may play more inductive roles in cancer progression. The subsets of proteins present in the conditioned media from cultured cells are referred to as 'secretomes' (Ref. 17) . Specifically, BEC-and LEC-secreted factors are referred to as 'angiocrine' (Ref. 18) and 'lymphangiocrine' factors, respectively (Ref. 19 ). These endothelium-derived factors are actively involved in tumour progression. Therefore, the understanding of the angiocrine and lymphangiocrine factors adds BEC and LEC to cancer-promoting orchestrators in microenvironments beyond their conventional roles as components of the passive conduits and suggests more improved, mechanism-based strategies upon current anti-angiogenic or antilymphangiogenic therapies.
In this review, we first discuss tumour and organ microenvironments, with a focus on angiogenesis and lymphangiogenesis in these microenvironments. We next discuss BEC-and LEC-secreted factors and their roles in cancer. Lastly, we address clinical implications and applications and outstanding research questions.
Microenvironment in cancer
Directly targeting tumour cells, which are genetically unstable and prone to mutations, often leads to resistance to therapy and a risk of tumour recurrence. However, because the non-cancer cell types in the tumour and organ microenvironments are genetically stable, targeting them and the microenvironmental regulation of tumour progression is an attractive alternative. Here we discuss two distinct microenvironments in cancer: the tumour microenvironment and the organ microenvironment.
Tumour microenvironment
The tumour microenvironment is the cellular environment in which the tumour exists and it consists of ECM and diverse types of nonmalignant cells, including cancer-associated fibroblasts (CAF), pericytes, macrophages, dendritic cells (DC), mast cells, lymphocytes, endothelial cells and their precursors in tumours (Ref. 4) . Among them, immune cells and mesenchymal cell types have been well studied.
Immunecells(e.g.macrophages,DC,lymphocytes and mast cells) are recruited to the TME where they express diverse tumour-promoting signals. Tumourassociated macrophages (TAM) are well-studied immune cell types and are generally known to be immunosuppressive and pro-angiogenic. TAM are one of the myeloid-derived suppressor cells (MDSC) (TIL) and their modifications are also crucial for tumour cell survival in TME (Refs 27, 28) . Although the TIL are supposed to be anti-tumourigenic, TME induces apoptosis of the TIL by secreting tumour exosomes that contain apoptosis ligands (Ref. 29) . T lymphocytes activity in TME can also be edited by LV activity. CCL21 expressed by the LV recruits CCR7-positive naive T cells into the lymphatic systems in the tumour stroma where they can be conditioned to be less immune reactive by tumoursecreted cytokines (Ref. 30) . Tumour-secreted TGFβ promotes tumour-associated regulatory T cell (T reg ) and MDSC activities. These cells impair cytotoxic T lymphocytes (CTL) and helper T1 cell functions (Ref. 30) .
Mesenchymal cell types, such as fibroblasts are also pivotal for tumour progression (Refs 31, 32 
BEC-mediated signals in cancer
As discussed above, tumour angiogenesis is a target for inhibiting tumour growth by blocking the supply of oxygen to the growing tumour. There have been a number of studies that show that BEC-cancer cell crosstalk regulates cancer cell proliferation and migration. Slit homologue protein 2 (Slit2), which is negatively regulated by Ephrin A2 receptor (EphA2) in BEC, is a breast tumour suppressive angiocrine factor (Ref. Crosstalk between LEC and cancer cells can facilitate the recruitment of cancer cells from the primary tumours to the lymphatic system. The lymphatic endothelium expresses CXCL12 and CCL21 chemokines and these chemokines recruit CXCR4-or CCR7-expressing cancer cells by chemoattraction (Refs 133, 134, 135 ). CXCL12 and CCL21 expression was observed in physiological LEC as well where they function to recruit immune cells to maintain host immunity. The chemokines secreted by LEC in highly metastatic oral cancer cell conditioned media was reported to be highly altered compared with that by normal LEC (Ref. 136 
LEC-mediated signals in cancer

Clinical implications and applications Therapeutic strategies to target blood and LV
Multiple strategies to target the tumour and organ microenvironments, particularly the BV and LV are in the clinic and in development. To target the BV in the microenvironment, several drugs, including the anti-VEGF monoclonal antibody bevacizumab, the receptor tyrosine kinase inhibitor sunitinib and the decoy receptor aflibercept (VEGF-trap) are clinically used. Anti-angiogenic monotherapy, such as anti-VEGF treatment, has shown limitation in clinic. This can be partially explained by that even after inhibiting single factor or pathway, other tumoursecreted factors or signals continue to support angiogenesis persistently (Refs 35, 145, 146, 147) . New data on the combination of anti-angiogenic therapies and other pathway blockages showed improved outcomes. For example, anti-VEGF therapy with COX-2 inhibition more potently blocked the angiogenesis, compared with just anti-VEGF treatment by blocking COX-2 derived prostaglandin E2 (PGE 2 ) production. PGE 2 is a VEGF-independent pro-angiogenic factor secreted by COX-2 expressing tumour cells (Ref. 148) . No drugs are clinically used to target the LV but some are in preclinical development. They mostly target VEGFC/D, VEGFR3 and NRP2. Although anti-angiogenic therapies have shown promising outcomes in reducing tumour size, a large number of patients suffer from tumour metastasis facilitated by tumour LV which current antiangiogenic agents are not able to inhibit. Specifically in breast cancer, tumour LV are the predominant routes of tumour dissemination. Thus current interest in the application of antiangiogenic agents as cancer therapeutics has led to strategies combining inhibitors of angiogenesis and lymphangiogenesis with the goal of developing more effective anti-cancer therapies (Refs 62, 105, 149, 150).
Therapeutic and diagnostic values of the tumour-endothelial crosstalk signals
As described in this review, BEC and LEC secretomes play important roles in tumour progression, suggesting that we can target tumour-endothelial crosstalk signals in addition to targeting conventional tumour angiogenesis and lymphangiogenesis. In our previous study, we found that breast tumour cell secreted IL6 educated LEC in the pre-metastatic organs to express CCL5 and facilitate metastatic breast tumour recruitment into those organs (Ref. 104) . In that study, we blocked IL6 and CCR5 resulting in dramatic reduction in lung and LN metastasis.
These signalling molecules governing tumour-endothelial crosstalk have a diagnostic value as well. Human sample-based bioinformatics analysis of TCGA (The Cancer Genome Atlas) showed higher levels of IL6 and CCL5 mRNAs in highly metastatic human triple-negative breast cancer (TNBC) tumour samples compared with those in less metastatic human oestrogen receptor positive (ER+) tumour samples. Furthermore, TNBC tumours obtained from LN positive patients showed better correlation of IL6 and CCL5 gene expression compared with those from LN negative patients. These results suggest that repurposing the antiretroviral CCR5 inhibitor (maraviroc) or the antirheumatoid arthritis IL6 receptor antibody (tocilizumab) for advanced and metastatic breast cancer may have substantial clinical benefit (Ref. 104) . Also these repurposed drugs can be combined with conventional anti-angiogenic drugs (e.g. anti-VEGF antibodies) or chemotherapies. For example, we showed that an anti-VEGF antibody exhibited additive anti-metastatic effects when it was combined with maraviroc.
Research in progress and outstanding research questions
Over the past 40 years, much progress has been made in understanding the role of angiogenesis in tumour growth and metastasis. This understanding has facilitated anti-angiogenic drug development to efficiently treat primary tumour growth in patients. It is very important that the current interest in tumour lymphangiogenesis also results in the development of drugs to target tumour LV formation and lymphogenous metastasis. Possibly these anti-angiogenic and antilymphangiogenic therapies can be combined with each other for improved outcomes for patients. Other recent studies of tumour and organ microenvironments have also contributed to our understanding of diverse non-cancer cell types that can promote tumour growth, metastasis, immune tolerance, drug resistance, etc. However, the perspective that BEC and LEC can be important orchestrators in the microenvironments are still under-appreciated compared with the role of other cell types such as immune cells, bone marrow-derived cells and mesenchymal like cells. Analyses of secretome of BEC and LEC from different kinds of tumours (breast, gastric, brain tumours, etc.), from metastatic versus non-metastatic tumours, from different sites of metastases (LN, lung, bone metastases, etc.) need to be further investigated to generate more informative secretome libraries. Tumour secretomes can cause dysregulation of endothelial secretomes, thus we also need to understand which factors (cytokines, nucleic acids, small molecules, etc.) in tumour secretomes are governing these tumour-promoting scenarios. 
